BioMarin Acquires Inozyme Pharma
San Francisco – May 16, 2025 – Cooley is advising BioMarin Pharmaceutical (Nasdaq: BMRN), a global biotechnology company dedicated to translating the promise of genetic discovery into medicines that make a profound impact on the life of each patient, on its definitive agreement to acquire Inozyme Pharma for $4 per share in an all-cash transaction valued at approximately $270 million. The transaction, unanimously approved by both companies’ boards of directors, is expected to close in the third quarter of 2025, subject to regulatory approval, successful completion of a tender offer and other customary closing conditions.
Cooley lawyers Jamie Leigh, Ben Beerle, Siana Lowrey and Chadwick Mills are leading the team advising BioMarin.
Cooley has represented BioMarin for 10+ years, including on its $600 million revolving credit facility in August 2024, a securities class action win before the US Court of Appeals for the Ninth Circuit in February 2024, its $550 million offering of 1.25% senior subordinated convertible notes due 2027 in May 2020, its licensing agreement with Allievex in October 2019, its $720 million follow-on offering in July 2018, its $450 million offering of 0.599% senior subordinated convertible notes due 2024 in August 2017, its $720 million follow-on offering in September 2016, its sale of its worldwide rights of talazoparib to Medivation in August 2015 and its $10 million acquisition of Zacharon in January 2013.
About Cooley LLP
Clients partner with Cooley on transformative deals, complex IP and regulatory matters, and high-stakes litigation.
Cooley has nearly 1,400 lawyers across 19 offices in the United States, Asia and Europe, and a total workforce of more than 3,000 people.
Related contacts
This content is provided for general informational purposes only, and your access or use of the content does not create an attorney-client relationship between you or your organization and Cooley LLP, Cooley (UK) LLP, or any other affiliated practice or entity (collectively referred to as “Cooley”). By accessing this content, you agree that the information provided does not constitute legal or other professional advice. This content is not a substitute for obtaining legal advice from a qualified attorney licensed in your jurisdiction and you should not act or refrain from acting based on this content. This content may be changed without notice. It is not guaranteed to be complete, correct or up to date, and it may not reflect the most current legal developments. Prior results do not guarantee a similar outcome. Do not send any confidential information to Cooley, as we do not have any duty to keep any information you provide to us confidential. This content may be considered Attorney Advertising and is subject to our legal notices.